Cord blood market segmentation is one of the most important (and least appreciated) parts of analyzing the cord blood banking industry. As the first and only market research firm to track the stem cell industry, BioInformant has collected over 16 years of historical information on the cord blood industry from 2006 to present. This provides a powerful record if past industry dynamics, as well as a robust platform for making future projections. [Read more…]
Stem cells are unique for the role they play. They are effectively the body’s raw material – the cells from which all other cells with specialized functions are created, such as those which constitute our blood, brain, or bone.
According to Sleepedia, that is not the only way they are unique. One of the defining features of stem cells is that unlike other cells, they don’t exhaust themselves. After undertaking their duties, they are able to enter a state of hibernation which allows for self-renewal.
They effectively go to sleep and in doing so they make themselves young again, a process known as reversible quiescence. In the body these sleeping stem cells can then remain dormant for years until called into action again. [Read more…]
– Data show rapid and durable engraftment with MGTA-456, an expanded cord blood stem cell product, in all 18 patients with hematologic malignancies across all conditioning regimens tested –
– MGTA-456 achieves clinical benefits of cord blood transplant –
– Clinically validated process to expand the numbers of CD34+ cells by >300 fold in single cord blood units significantly increases probability of identifying better HLA-matched stem cell donors for patients
December 11, 2017, CAMBRIDGE, Mass.–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 hematopoietic stem cell (HSC) expansion program at the 59th annual meeting of the American Society of Hematology (ASH) in Atlanta, Ga. MGTA-456 is a single umbilical cord blood unit expanded with an aryl hydrocarbon receptor (AHR) antagonist. It is currently being studied in adult and pediatric patients with hematologic malignancies.
Over the past five years, the global cord blood banking market has substantially matured and consolidated. This has created both serious threats and novel opportunities for the industry. Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation.
Marketing pressures are also impacting the industry, with the term “cord blood” being one of the 20 most expensive search terms on Google. Winning online traffic through Google AdWords for the search phrase “Cord Blood” now costs $45.87 in the U.S. When all locations are allowed, the cost for acquiring online traffic through Google AdWords for the phrase “Cord Blood” is $32.91. [Read more…]
Phase 3 study of NiCord commenced last month in blood cancer patients
Jerusalem, Israel, March 23, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that orphan drug designation has been granted by the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) regarding NiCord® as a treatment for haematopoietic stem cell transplantation, also commonly known as bone marrow transplantation (BMT).
“We are very encouraged that the EMA has widened NiCord’s orphan drug designation to include BMT, and believe it is an important recognition of the unmet needs in these indications,” said Gamida Cell president and CEO Dr. Yael Margolin. “This broadened regulatory designation adds a key layer of market exclusivity for NiCord as we move forward with our Phase 3 study and prepare for commercialization.” [Read more…]